Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis

Critical Care Medicine

Volumn 30, Issue 5 SUPPL., 2002, Pages

  Dhainaut, Jean François ^a   Yan, S Betty ^a   Cariou, Alain ^a   Mira, Jean Paul ^a  

^a University of Paris V ^*  (France)

Author keywords

Activated protein C; Disseminated intravascular coagulation; Plasma derived protein C; Protein C; Sepsis; Shock; Soluble thrombomodulin; Thrombomodulin

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; PROTEIN C; THROMBIN; THROMBOMODULIN; VITAMIN K GROUP;

ANTICOAGULATION; BLOOD CLOTTING DISORDER; CELL ACTIVATION; CONFERENCE PAPER; DRUG ACTIVITY; HUMAN; INFLAMMATION; MENINGOCOCCEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; THROMBOCYTE ACTIVATION;

EID: 0036254955     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200205001-00023     Document Type: Conference Paper

References (77)

1. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
2. The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error
3. Toll-like receptors in the induction of the innate immune response
4. Pathogenetic mechanisms of septic shock
5. Experimental endotoxin in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
6. Cytokines and anticytokines in the pathogenesis of sepsis
7. Review: Infectious diseases and coagulation disorders
8. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
9. How coagulation defects alter outcome in sepsis: Survival may depend on reversing procoagulant conditions
10. Sepsis/septic shock: Participation of the microcirculation: An abbreviated review
11. Disseminated intravascular coagulation
12. Role of the coagulation system in the local and systemic inflammatory response
13. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
14. Pathogenesis of focal and random hepatocellular necrosis in endotoxemia: Microscopic observation in vivo
15. Dysfunction of endothelial protein C activation in severe meningococcal sepsis
16. Sepsis and septic shock: Proinflammatory or anti-inflammatory state?
17. Sepsis: A new hypothesis for pathogenesis of the disease process
18. Inhibitory cytokines
19. The proinflammatory cytokine cascade
20. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock
21. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway
22. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects
23. The roles of protein C and thrombomodulin in the regulation of blood coagulation
24. Endothelial protein C receptor
25. Changes of the hemostatic network in critically ill patients: Is there a difference between sepsis, trauma, and neurosurgery patients?
26. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
27. Septic shock, multiple organ failure and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies
28. Time course of hemostatic abnormalities in sepsis and its relation to outcome
29. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency
30. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications
31. Low levels of protein C are associated with poor outcome in severe sepsis
32. The effect of leukocyte elastase on protein C and activated protein C
33. Hepatic response to sepsis: Interaction between coagulation and inflammatory processes
34. Regulation of thrombomodulin by tumor necrosis factor-alpha: Comparison of transcriptional and posttranslational mechanisms
35. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro
36. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
37. Modulation of human endothelial thrombomodulin by neutrophils and their release products
38. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo
39. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes
40. Effect of intradermal tumor necrosis factor α-induced inflammation on coagulation factors in dermal vessel endothelium
41. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: Toward a better definition of DIC
42. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
43. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis
44. Recombinant human APC (LY203638)-induced reperfusion in a canine model of occlusive coronary artery thrombosis
45. The profibrinolytic effect of APC in clots formed from plasma is TAFI-dependent
46. Novel antithrombotics based on modulation of the protein C pathway
47. The normal role of APC in maintaining homeostasis and its relevance to critical illness
48. The endothelial cell protein C receptor
49. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway
50. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production
51. APC inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor-κB (NF-κB) and tumor necrosis factor-α (TNF-α) production in the THP-1 monocyte cell line
52. Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin
53. Different glycoforms of human thrombomodulin: Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III
54. Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: Thrombomodulin associates with free thrombin and is recycled to activate protein C
55. The glycosylation sites and structural characteristics of oligosaccharides on recombinant human thrombomodulin
56. Structural analysis of the sugar chains of human urinary thrombomodulin
57. Demonstration of the immature glycosaminoglycan tetrasaccharide sequence GlcAβ1-3Galβ1-3Galβ1-4Xyl on recombinant soluble human α-thrombomodulin. An oligosaccharide structure on a "part-time" proteoglycan
58. 4-3GlcAβ1-3Galβ1-3(±Siaα2-6)Galβ1- 4Xyl
59. New potential therapeutic modalities: APC
60. The glycosaminoglycan of the recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced DIC
61. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis)
62. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced DIC in rats
63. Recombinant human soluble thrombomodulin reduces endotin-induced pulmonary vascular injury via protein C activation in rats
64. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats
65. rhs-TM prevents ET-induced increase on pulmonary vascular permeability through protein C activation
66. The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats
67. Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers
68. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
69. Treatment of purpura fulminans in meningococcemia with protein C concentrate
70. Use of protein C concentrate, heparin, haemofiltration in meningococcus-induced purpura fulminans
71. Severe acquired protein C deficiency in purpura fulminans associated with DIC: Treatment with protein C concentrate
72. An update on clinical and basic aspects of the protein C anticoagulant pathway
73. Effects of combined antithrombin III and protein C supplementation in porcine acute endotoxin shock
74. APC concentrate for the treatment of meningococcal endotoxin shock in rabbits
75. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
76. Efficacy and safety of recombinant human APC for severe sepsis
77. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis